Clinical Context
A typical patient receiving Q5104 is an adult with an immune-mediated inflammatory disease such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn disease, or ulcerative colitis who requires maintenance intravenous biologic therapy with an infliximab biosimilar (renflexis). The clinical workflow begins with a physician visit by a rheumatologist, gastroenterologist, or infusion center medical director who documents indication, prior response to therapy, weight-based dosing calculation, and screening for active infections (including tuberculosis and hepatitis B). Prior authorization is frequently obtained from payors including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthCare, BUCA, or Medicare. On the infusion day the patient is triaged, vital signs recorded, premedication ordered as needed (acetaminophen, antihistamine, corticosteroid), and an intravenous line placed by a registered nurse. The Q5104 drug vial is prepared by pharmacy, delivered to the infusion suite, administered per product-specific infusion rate with monitoring for infusion reactions, and post-infusion observation is performed. Documentation includes medication name infliximab-abda (renflexis), NDC and lot number, dose in mg, infusion start and stop times, patient tolerance, and any concurrent administration codes or modifiers (for example reporting wasted drug using JW when applicable). Billing is submitted to the patient’s primary insurer with the appropriate HCPCS code Q5104, diagnosis code(s) supporting medical necessity, and relevant modifiers for payment circumstances or administration complexities.